Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£123.38 -92.00 (-0.74%)
As of 05:09 AM Eastern
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings
Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for AZN.

Consensus Price Target

£150
According to the 7 analysts' twelve-month price targets for AstraZeneca, the average price target is £150. The highest price target for AZN is £178, while the lowest price target for AZN is £117. The average price target represents a forecasted upside of 21.58% from the current price of £123.38.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
9/24/25 to 9/24/26		1 Month Ago
8/25/25 to 8/25/26		3 Months Ago
6/26/25 to 6/26/26		1 Year Ago
9/24/24 to 9/24/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£150£152.17£153.33£131.75
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaHealthcare Companies
Consensus Rating Score
2.86
2.31
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/15/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Reiterated RatingSell ➝ Hold£117-3.35%
9/15/2026
Berenberg Bank logo
Berenberg Bank
2 of 5 stars
 Lower TargetBuy£160 ➝ £150+24.23%
9/9/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
3 of 5 stars
 Reiterated RatingBuy£175+47.95%
9/8/2026
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform£145+22.59%
7/28/2026
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy£175 ➝ £178+39.50%
1/16/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/15/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:30 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 22, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • Recent clinical success with Enhertu, which improved progression-free survival by six months in a first-line trial for HER2-mutant non-small-cell lung cancer, supports the commercial and clinical potential of the company's oncology partnership and strengthens its pipeline.
  • Insider confidence is evident as Michel Demare, the Non-Executive Chair of the Board, purchased 2,500 shares of the company's stock on September 14, 2026, at an average price of £121.21 per share, signaling a positive outlook from senior leadership.
  • The FDA granted priority review to AstraZeneca's efzimfotase alfa for bone disease, a regulatory milestone that could accelerate the drug's market entry and contribute to future revenue growth in the cardiovascular, renal, and metabolism therapy area.
  • With a current stock price of $12,560.00, the company offers a dividend yield of 1.92%, providing a steady income stream for investors while maintaining a moderate beta of 0.21, which suggests lower volatility compared to the broader market.
  • Analyst sentiment remains favorable with a consensus rating of Moderate Buy and an average price target of £150, indicating that Wall Street sees potential for the stock to rise from its current levels despite recent mixed trial results.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • AstraZeneca's Etcamah combination failed to meet the primary endpoint in the Phase III SERENA-4 trial, a significant setback that could weaken expectations for the treatment's future revenue contribution and create near-term pressure on the shares.
  • The company's financial position shows a debt-to-equity ratio of 64.10 and a current ratio of 0.89, indicating that current liabilities exceed current assets, which may limit financial flexibility in the short term.
  • Some analysts have expressed caution, with Deutsche Bank maintaining a Hold rating and a price target of £117, which is below the current stock price, suggesting limited near-term upside at their valuation.
  • Berenberg Bank reduced its price target on shares of AstraZeneca from £160 to £150, reflecting more cautious expectations despite retaining a Buy rating, which may temper investor enthusiasm for significant price appreciation.
  • Jim Cramer, host of Mad Money, expressed nervousness about the company, noting that it has been missing some of its trials and questioning whether its COPD portfolio is sufficient to drive growth, highlighting concerns about execution risk.

AZN Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £150, with a high forecast of £178 and a low forecast of £117.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 21.58% based on their 12-month stock forecasts.

Over the previous 90 days, AstraZeneca's stock had 1 downgrade by analysts.

AstraZeneca has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and Royal Bank Of Canada in the past 90 days.

Analysts like AstraZeneca more than other "healthcare" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how AZN compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations


MarketBeat monitors more than a dozen sources for AstraZeneca analyst ratings, with the most recent rating issued on 9/15/2026.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel